Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Galimedix Therapeutics, a biotechnology company, has announced the initiation of a Phase 1 study for its oral small molecule, GAL-101. This study aims to assess the safety, tolerability, and pharmacokinetics of GAL-101 in single and multiple ascending doses in healthy volunteers. The company plans to explore the drug's potential for treating Alzheimer's disease, dry age-related macular degeneration (AMD), and glaucoma.

The study will include up to 72 participants across different dosing plans, with a total enrollment target of 120 subjects. GAL-101's capability to cross the blood-brain barrier will be examined, alongside other parameters. GAL-101 is recognized for targeting misfolded amyloid beta monomers, preventing harmful aggregates.

Previous studies with GAL-101 eyedrops have shown promising results in safety and efficacy, particularly in neurodegenerative models. The company is set to start a Phase 2 study with GAL-101 eyedrops for dry AMD shortly.